TG Therapeutics Files 8-K on Operations and Financials
Ticker: TGTX · Form: 8-K · Filed: Nov 4, 2024 · CIK: 1001316
Sentiment: neutral
Topics: reporting, financials
Related Tickers: TGTX
TL;DR
TG Therapeutics dropped an 8-K on Nov 4th covering financials and ops - check it for the latest.
AI Summary
TG Therapeutics, Inc. filed an 8-K on November 4, 2024, reporting on its results of operations and financial condition, and including financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.
Why It Matters
This filing serves as an official update to the SEC regarding TG Therapeutics' financial status and operational results, which is crucial for investors to assess the company's performance and outlook.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting event and does not inherently contain new negative information or significant risk factors.
Key Players & Entities
- TG Therapeutics, Inc. (company) — Registrant
- November 4, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-32639 (identifier) — Commission File Number
- 36-3898269 (identifier) — IRS Employer Identification No.
FAQ
What specific financial results are being reported in this 8-K?
The provided text indicates the filing is related to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but does not detail the specific financial figures within this excerpt.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on November 4, 2024.
What is the Commission File Number for TG Therapeutics, Inc.?
The Commission File Number for TG Therapeutics, Inc. is 001-32639.
In which state was TG Therapeutics, Inc. incorporated?
TG Therapeutics, Inc. was incorporated in Delaware.
What is the IRS Employer Identification Number for TG Therapeutics, Inc.?
The IRS Employer Identification Number for TG Therapeutics, Inc. is 36-3898269.
Filing Stats: 505 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-11-04 07:19:19
Filing Documents
- tgtx20241103_8k.htm (8-K) — 25KB
- ex_742243.htm (EX-99.1) — 156KB
- 0001437749-24-033055.txt ( ) — 328KB
- tgtx-20241104.xsd (EX-101.SCH) — 3KB
- tgtx-20241104_def.xml (EX-101.DEF) — 11KB
- tgtx-20241104_lab.xml (EX-101.LAB) — 15KB
- tgtx-20241104_pre.xml (EX-101.PRE) — 11KB
- tgtx20241103_8k_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On November 4, 2024, the Company issued a press release announcing results of operations for the three and nine months ended September 30, 2024. A copy of such press release is being furnished as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 hereto), shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by TG Therapeutics, Inc., dated November 4, 2024. Exhibit 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TG Therapeutics, Inc. (Registrant) Date: November 4, 2024 By: /s/ Sean A. Power Sean A. Power Chief Financial Officer